Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.067 Leser
Artikel bewerten:
(2)

MPLC Announces Passing of Chief Executive Officer Mike Weatherley

Finanznachrichten News

LOS ANGELES, May 22, 2021 /PRNewswire/ -- MPLC is saddened to announce the passing of beloved CEO, Mike Weatherley on Thursday May 20 due to unexpected complications arising from lung cancer. He is survived by three children and two grandchildren.

MPLC

A former member of the UK Parliament (MP) (2010 to 2015), Mike was a fierce champion of intellectual property rights, serving as the first, and only, Intellectual Property Rights Advisor to Prime Minister David Cameron. During his tenure, he authored four internationally acclaimed reports which transformed the UK approach to intellectual property: Search Engines and Piracy; Follow the Money; Copyright, Education and Awareness; and Safe Harbour Provisions and Online Service Providers. Most recently, Mike was named to the 2020 edition of IAM Strategy 300: The World's Leading IP Strategists.

Mike's passion for intellectual property stemmed from his love of music, especially heavy metal. He famously promised constituents to wear his Iron Maiden t-shirt in the House of Commons once elected, a promise he was only able to partially fulfil after the speaker said, no. In his capacity as MPLC CEO, Mike could be seen wearing his Iron Maiden t-shirts on casual dress days.

Mike began his tenure in MPLC's UK organization in 2007. As Vice President, Europe, he worked closely with Finance and European Rights Holders. In May 2015, after concluding his time in parliament, he returned to the firm as Vice Chairman, splitting his time between Los Angeles and Eastbourne. His responsibilities included international rights holder and government relations, worldwide group finance, and corporate and strategic development. He was instrumental in MPLC's renewed Asia expansion, overseeing the launch of the firm's Hong Kong office in 2018.

In January 2019, Mike was named CEO and quickly implemented an ambitious growth strategy for the firm, negotiating a partnership with Tenzing Private Equity, a London-based growth equity investor. A series of strategic executive hires followed as well as continued expansion into Taiwan, Thailand, and western Asia. Mike summarized his ambitions for this phase of the firm's growth with a simple strapline he evangelized to both employees and rights holders, "to become the de facto standard and most professional non-theatrical licensing company in the world."

Louise Rogers, Chair-elect of the MPLC Board, has been named interim CEO. "Mike was an amazing CEO, a mentor, and an inspirational leader. He loved being CEO and was determined to beat his illness and get back to helping us drive forward. He never gave up and never failed to put MPLC, and all of us, before himself. He was a visionary and will be sorely missed."

About MPLC: MPLC is the global leader in non-theatrical licensing, supporting legal public performances of motion pictures, television, and other audiovisual content in more than 40 countries around the world. Under the Umbrella License, a blanket license for public performance, MPLC represents rights holders ranging from major Hollywood studios to independent producers. MPLC licensees include government, corporations, and non-profit organizations. Hundreds of thousands of locations around the world publicly perform content legally with the Umbrella License.

Mike Weatherley

Logo - https://mma.prnewswire.com/media/1516361/MPLC_Logo.jpg

Photo - https://mma.prnewswire.com/media/1516362/MPLC_Mike_Weatherley.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.